CTI BioPharma (CTIC) Misses Q4 EPS by 9c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to CTI BioPharma (CTIC) Misses Q4 EPS by 9c, Offers Guidance
March 12, 2015 4:01 PM EDT
SEATTLE, March 12, 2015 /PRNewswire/ --Â CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2014.
"In 2014, we successfully accomplished various key company objectives, from achieving reimbursement in England/Wales and securing a development and commercialization collaboration for PIXUVRI®, to pacritinib receiving Fast Track designation by the U.S. FDA and reporting on data highlighting pacritinib's potential therapeutic utility in blood-related cancer indications beyond myelofibrosis," said James A. Bianco, M.D., CTI BioPharma's President and CEO. "Now, with positive... More
